{"filing":{"accession_number":"0001654954-26-006954","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"a1993o.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006954/a1993o.htm"},"events":[{"id":20997,"run_id":18921,"accession_number":"0001654954-26-006954","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GSK announced a major strategic R\u0026D investment and operational restructuring: establishment of a new £400 million flagship R\u0026D centre in Cambridge over 3 years, relocation of over 1,000 scientists from Stevenage by 2029, and upgrades to Ware facilities. This is a material operational and strategic business event involving significant capital deployment and workforce repositioning, but does not fit the specific categories of M\u0026A, workforce reduction (though it involves relocation), or other named types. It is clearly operational in nature and would affect a reasonable investor's assessment of GSK's R\u0026D strategy and capital allocation.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":20523,"accession_number":"0001654954-26-006954","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"GSK announced a major strategic R\u0026D investment and operational restructuring: establishment of a new £400 million flagship R\u0026D centre in Cambridge over 3 years, relocation of over 1,000 scientists from Stevenage by 2029, and upgrades to Ware facilities. This is a material operational and strategic business event involving significant capital deployment and workforce repositioning, but does not fit the specific categories of M\u0026A, workforce reduction (though it involves relocation), or other named types. It is clearly operational in nature and would affect a reasonable investor's assessment of GSK's R\u0026D strategy and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T17:10:36.696519+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-28"}]}